Aratana Therapeutics Q4 Earnings Preview

Aratana Therapeutics PETX announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Analysts covering Aratana Therapeutics have modeled for quarterly EPS loss of 22 cents per share on revenue of $6.82 million.

Aratana Therapeutics EPS loss in the same period a year ago came in at 35 cents and sales were $292,000. The Wall Street estimate would represent a 37.14 percent increase in the company's earnings. Sales would be up 2235.62 percent on a year-over-year basis.

Here's how the company's reported EPS has compared to analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are down 35.19 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The popular rating by analysts on Aratana Therapeutics stock is a Buy. The strength of this rating has risen over the past 90 days.